$REPL
Based on FDA’s own published analysis as well as discussions at the adcom, IGNYTE does not reliably establish the true efficacy of RP1 plus nivolumab or the specific contribution of RP1 to that combination therapy. Unless FDA has important nonpublic evidence that resolves
